P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations with Non-Adenocartinoma Histology

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have substantial anti-tumor activity for NSCLC harboring EGFR sensitizing mutations. Adenocarcinoma (ADC) is the most common histological subtypes in patients with NSCLC harboring EGFR mutations. Whereas, EGFR mutations are occasionally observed in other histological subtypes of NSCLC. However, little is known about the efficacy of EGFR-TKIs in patients with...